The World Health Organisation (WHO) said last weekend that the vaccine, developed by GlaxoSmithKline through a network of African research centres, will be rolled out in pilot projects in sub-Saharan Africa. Here in Tanzania, it involved scientists from the Ifakara Health Institute (IHI). RTS, S is the first malaria vaccine to have successfully completed pivotal Phase 3 testing.
